Quidel Corporation (QDEL) – Research Analysts’ Recent Ratings Updates

Quidel Corporation (NASDAQ: QDEL) has recently received a number of price target changes and ratings updates:

  • 7/31/2017 – Quidel Corporation was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/29/2017 – Quidel Corporation was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong sell” rating. According to Zacks, “Quidel Corp. discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that affect women’s health throughout the phases of their lives including reproductive status, pregnancy management and osteoporosis. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia and infectious mononucleosis. “
  • 7/27/2017 – Quidel Corporation had its price target raised by analysts at Raymond James Financial, Inc. from $36.00 to $41.00. They now have an “outperform” rating on the stock.
  • 7/27/2017 – Quidel Corporation had its price target raised by analysts at Barclays PLC from $36.00 to $39.00. They now have an “overweight” rating on the stock.
  • 7/26/2017 – Quidel Corporation was downgraded by analysts at TheStreet from a “b-” rating to a “c” rating.
  • 7/21/2017 – Quidel Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Quidel Corp. discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that affect women’s health throughout the phases of their lives including reproductive status, pregnancy management and osteoporosis. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia and infectious mononucleosis. “
  • 7/18/2017 – Quidel Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $30.00 price target on the stock. According to Zacks, “Quidel Corp. discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that affect women’s health throughout the phases of their lives including reproductive status, pregnancy management and osteoporosis. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia and infectious mononucleosis. “
  • 7/18/2017 – Quidel Corporation was upgraded by analysts at William Blair from a “market perform” rating to an “outperform” rating.
  • 7/18/2017 – Quidel Corporation was upgraded by analysts at Canaccord Genuity from a “hold” rating to a “buy” rating.
  • 7/16/2017 – Quidel Corporation was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 7/6/2017 – Quidel Corporation was upgraded by analysts at TheStreet from a “c+” rating to a “b-” rating.

Shares of Quidel Corporation (QDEL) opened at 32.24 on Wednesday. The firm’s market cap is $1.08 billion. The firm has a 50-day moving average price of $30.40 and a 200-day moving average price of $24.49. Quidel Corporation has a 52-week low of $18.25 and a 52-week high of $38.92.

Quidel Corporation (NASDAQ:QDEL) last released its quarterly earnings data on Wednesday, July 26th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.18. The firm had revenue of $38.30 million for the quarter, compared to analyst estimates of $41.91 million. Quidel Corporation had a negative return on equity of 0.03% and a negative net margin of 0.03%. The firm’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.11) earnings per share. Analysts predict that Quidel Corporation will post $0.28 EPS for the current fiscal year.

In other news, CEO Douglas C. Bryant sold 36,000 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $33.83, for a total transaction of $1,217,880.00. Following the completion of the sale, the chief executive officer now owns 296,493 shares of the company’s stock, valued at approximately $10,030,358.19. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Randall J. Steward sold 94,215 shares of the company’s stock in a transaction that occurred on Friday, July 28th. The stock was sold at an average price of $34.09, for a total transaction of $3,211,789.35. Following the sale, the chief financial officer now directly owns 79,907 shares of the company’s stock, valued at approximately $2,724,029.63. The disclosure for this sale can be found here. Insiders sold a total of 227,388 shares of company stock valued at $6,951,432 in the last three months. Insiders own 22.00% of the company’s stock.

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.

Receive News & Ratings for Quidel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply